Literature DB >> 30561407

Epidemiology and risk factors of pancreatic cancer.

Mario Capasso1, Marilisa Franceschi, Kryssia Isabel Rodriguez-Castro, Pellegrino Crafa, Ginevra Cambiè, Chiara Miraglia, Alberto Barchi, Antonio Nouvenne, Gioacchino Leandro, Tiziana Meschi, Gian Luigi De' Angelis, Francesco Di Mario.   

Abstract

The most frequent pancreatic cancer is pancreatic adenocarcinoma. It has high and early locally and distant invasiveness; this is the reason why it often shows little sign or symptoms in early stage and poor prognosis after the diagnosis, frequently in advanced stage. Although it is possible to detect this tumor in early stage because of its neoplastic precursor (PanINs). Epidemiological data shows that pancreatic cancer is not very common but obvious it is one of the most neoplastic death-cause in the world. The trend of incidence is quite increasing through years, proportionally to the increase of risk factors. About risk factors, it is not easy to detect in all the cases but it is known the role of some of that: there are hereditary risk factors, such as genetic pattern like HBOC, HNPCC, FAP, PJS, FAMMM, HP and CF and environmental ones (modifiable) such as smoke, alcohol consumption, chronic pancreatitis, obesity and diabetes mellitus. This narrative review aims to analyze the epidemiological data of pancreatic cancer and associated risk factors.

Entities:  

Mesh:

Year:  2018        PMID: 30561407      PMCID: PMC6502190          DOI: 10.23750/abm.v89i9-S.7923

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


Introduction

All the pancreatic epithelial tumors are classified by WHO as benign (we will not consider these tumors in this review) and malignant ones; they are split out considering some macroscopic and microscopic features: on a macroscopic level they are solid, cystic or intraductal, while on a microscopic level they are ductal, acinar or endocrine tumors. The most frequent pancreatic malignant tumor is the solid one represented by ductal cells and it is called Pancreatic Ductal Adenocarcinoma with his variants (1). In this review we’re only considering pancreatic adenocarcinoma referring to it as “pancreatic cancer”. About its behavior, pancreatic cancer has high invasiveness and the tendency to infiltrate peri-pancreatic tissues, in addiction to that, it has high trend to show nodal metastasis (peri-pancreatic, gastric, mesenteric, omental and peri-portal nodes) and hepatic, bone or pulmonary metastasis. Rarely pancreatic cancer manifests specific signs or symptoms and because of its poorness of symptoms, it is often diagnosed in an advanced stage; frequently, when patients have symptoms like asthenia, jaundice, abdominal pain and weight loss, they already have a local advanced pancreatic neoplasia. On a biological level pancreatic cancer has a clear multistep carcinogenesis; just as colo-rectal cancer presents the adenoma-carcinoma sequence, pancreatic cancer shows a similar one starting from Pancreatic Intraductal Neoplasia (PanINs IA, IB, II and III) and ending with an invasive neoplastic lesion. PanINs’ progression is supported by a succession of a lot of gene mutations (2). This specific multistep carcinogenesis suggests that if we will diagnose an early stage lesion, by means of PanINs’ detection, we could stop the progression mentioned above, treating early lesions. This is the safer way to change the natural history of pancreatic cancer. Unfortunately, early-stage pancreatic cancer is usually clinically silent, highlighting the need for improved methods of early detection of precursor. All the above-mentioned aspects show that pancreatic cancer is one of the most big killing neoplasia loaded by a poor prognosis after diagnosis; in this context, the key to solve this problem is the primary prevention knowing the epidemiology and the risk factors associated. In this review, the purpose is to define the epidemiology of pancreatic cancer by means of descriptive data coming from the literature and identify risk factors associated with this cancer.

Epidemiology

In 1999 Parkin D et al. had compared cancer registries to obtain the incidences and mortality data bank to obtain information on cancer death in 23 world areas. The result was that pancreatic cancer was responsible for 168,000 deaths per year and it was the 9th most common cause of death from cancer in both sexes combined and about incidence it was the 13th. Unfortunately the mortality to incidence ratio was 98% because of the poor prognosis, worse in developed countries than in developing ones (3). To investigate the most recent worldwide epidemiology, we are basing our research on the GLOBOCAN estimates. The Global Cancer Observatory (GCO) is an interactive web-based platform presenting global cancer statistics to inform cancer control and cancer research. Incidence and mortality rates were estimated using GLOBOCAN by country, using the most recently available data collected by the IARC or available in routine reports from the registries themselves. GLOBOCAN 2012 estimates demonstrate different results of incidence and mortality, both lower than 350,000 (338,000 were new cases and 331,000 were the deaths); but already 6 years ago pancreatic cancer was the 7th leading cause of cancer death in both sexes and it was more frequent in developed countries (4). GLOBOCAN 2018 estimates show that, worldwide, pancreatic cancer is the 14th neoplasia sorting by new cases per year. There is little difference between male and female incidence rate. Because of its poor prognosis, with almost as many deaths (n = 432,000) as cases (n = 459,000), pancreatic cancer is the 7th leading cause of cancer death in both males and females (5). The trend of incidence of pancreatic cancer through years is increasing as reported by the recent Cancer Statistics Review (CSR) (6). Several authors, agree with that result, such as in Taiwan Tseng CM et al., analyzing Taiwan National Cancer Registry and the National Cause of Death Registry, support the evidence we mentioned above and they formulate that presumably the incidence and mortality will continue to rise in Taiwan (7). In Germany, Quante AS et al. have noted a constant increase in the incidence of pancreatic cancer, which will surpass colorectal and breast cancer to rank as the second most common cause of cancer-related deaths by 2030 (8); this trend is the same we can observe in US, where current projections suggest that pancreatic cancer will become the second-highest cause of cancer death (9). Finally we show the epidemiological data in Italy: in 2017 there was over 13,000 new cases and in 2015 over 11,000 deaths; in 2016 the incidence was 22/100,000 new cases per year and it is raising in both sexes, even if more in male population (10). Pancreatic cancer is mostly frequent in elderly people, the risk of developing pancreatic cancer goes up as people age: about 80% are at least 60 years old and 71 is the average age at the time of diagnosis (11). A population-based epidemiological sudy (12) conclude that the secular trends in the incidence of pancreatic cancer match trends in the prevalence in known risk factors for pancreatic adenocarcinoma such as smoking, overweight and obesity, and diabetes.

Risk factors

Despite other gastrointestinal tumors, evidences of risk factors for development of pancreatic cancer are poor and they don’t explain the whole pancreatic cancer world: we can identify risks factor only in 40% of cases. We have genetics factors (10%) and environmental (modifiable) factors (13). Curiously, it is difficult to understand the effect-cause relationship of some risk factors, such as diabetes mellitus: in literature some authors tried to clarify the question (14). About unmodifiable (hereditary) risk factors, we can remember: HBOC (Hereditary breast and ovarian cancer syndrome): the BRCA1 and BRCA2 mutations can cause early-onset malignant tumors, most of all breast and ovarian cancer, and including pancreatic cancer, especially if in BRCA2 mutation. This pathway can explain 17-19% of hereditary pancreatic cancer (15). HNPCC (Hereditary Non Polyposic Colorectal Cancer or Lynch syndrome): people who have Lynch syndrome, because of the microsatellite instability (MSH2, MSH6, MLH1, PMS2 and EPCAM genes), are predisposed to early-onset colorectal cancer without polyposic lesions and other-site neoplasia, including pancreatic cancer (RR=8.6) (16). FAP (Familial Adenomatous polyposis): this syndrome, caused by a mutation in the APC gene, is characterized of early-onset polyps in gastrointestinal tract that can be develop in malignant neoplasia. If FAP is involved in an increased risk of pancreatic cancer is uncertain because it may reflects a misdiagnosed of ampulla carcinomas (17). PJS (Peutz-Jeghers Syndrome): The STK11/LKB1 genes mutation characterize an hamartomatous polyposis syndrome and this condition can determine gastrointestinal neoplasia and other tumors like pancreatic cancer (RR=132) (18). FAMMM (Familial Athypical Multiple Mole Melanoma syndrome): this syndrome is characterized by malignant melanoma in one or more first-degree or second-degree relatives. In 38% of cases this pathology is caused by a p16INK4a gene mutation, dysregulates the normal cellular cycle. These people have an higher relative risk for pancreatic cancer (13 to 22-fold increased risk of developing pancreatic cancer) (19). HP (Hereditary Pancreatitis): In 80% of cases of hereditary pancreatitis it is possible to identify a PRSS1 gene mutation: this is a condition characterized by recurrent acute pancreatitis starting in childhood, that can be evolve in a praecox pancreatic failure (20); the pathogenetic mechanisms, involved in pancreatic cancer onset, are triggered by the pancreatic chronic inflammation (21). Some authors found an high relative risk (RR= 69) for pancreatic cancer for patients with HP compared to the general population (22). CF (Cystic Fibrosis): this pathology, caused by CFTR gene mutation, has the same pathogenetic mechanisms explained in HP, because recurrent acute pancreatitis can be involved in pancreatic cancer onset (23). More interesting is the acknowledgment about environmental risk factors: Tobacco use: smoking is the main demonstrated environmental risk factor for the development of pancreatic cancer; the pathogenetic mechanisms include genes mutations inducement (KRAS, p53) and, on the other hand, a chronic inflammation and these two factors can induce cytokines and growth factors output, providing the right pathway to cellular transformation. Tobacco smoking habits in considered responsible of 20-35% of pancreatic cancer cases (24). Alcohol consumption: the evidence of this association is limited to heavy alcohol assumption: more than three drinks consumption per day has a relative risk from 1.22 to 1.36 of developing pancreatic cancer, with a dose-response relationship. Alcohol and its metabolites make a pro-carcinogenetic pathway through chronic inflammation (considering alcohol consumption is responsible of 60-90% of chronic pancreatitis) and cellular gene instability (25). Chronic pancreatitis: The morphological and functional modification in chronic pancreatitis are the same we can found in pancreatic cancer; this similarity is represented also on a molecular level. The chronic inflammation causes the production of TNFα, IL-6, IL-8, PDGF, TGFβ and other cytokines that can induce cellular proliferation and reduce immune-surveillance (26). The main damage on DNA is caused by ROS production, promoting the progression to cellular transformation (27). The risk of pancreatic cancer is significantly elevated in subjects with chronic pancreatitis and appears to be independent from sex, country, and type of pancreatitis (28). In a 2010 meta-analysis, Raimondi S. et al. identify the association between chronic pancreatitis and pancreatic cancer with a 13.3 relative risk (22). Obesity: Some studies had demonstrated a relative risk increase of 1.12 for each increase in 5 kg/m2 in the BMI (29). In obese people the pathogenesis is characterized by adiposopathy, a chronic adipose disease in which macrophages product pro-inflammatory cytokines and there is a dysregulation of hormonal level: in particular we can find high level of leptin and low level of adiponectin (30). It is interesting to observe that there is a temporal relationship between BMI and the neoplasia: obesity since childhood have a higher risk relative for pancreatic cancer development (31). On a dietetic level, high consumption of red meat and fatty diet may have a role in the pathogenesis (32). Diabetes mellitus: About 80% of people with pancreatic cancer have also glucose intolerance or diabetes. The association between these two diseases is clear but it is important to define the relationship. The majority of patients with pancreatic cancer has diabetes in close up the diagnosis of the tumor validating the hypothesis which support that this diabetes is a consequence of the neoplasia (33). But there is a relevant association also with diabetes mellitus type 2 with OR=1.8 (34); the pathogenetic mechanisms sustain this relationship are the hyperinsulinemia, often detected in DMT2, and high level of IGF1: that modification can induce pancreatic glandular proliferation and specific cellular interaction (35). The cellular interaction is between Pancreatic Stellate Cells (PaSCs) and Tumor-associated Macrophages (TAMs): while their dysregulation, because of hyperinsulinemia and hyperglycemia, can induce fibrosis, cellular proliferation and apoptosis inhibition, they are the actors of desmoplastic reaction and hyperplasia frequently detected in pancreatic neoplastic tissues (36). There are some others factors pointed to have a role in pancreatic carcinogenesis, but there isn’t enough evidence in literature, e.g. biliary obstructive diseases. Some studies underline the role of cholecystectomy: the pivot of this association is the CCK levels, often high in cholecystectomized patients, CCK is responsible for pancreatic glandular hyperplasia (RR=1.23) (37). Some other studies support the hypothesis according to which the risk factor isn’t the surgery but the history of gallstones (RR=1.70) (38). We have to consider that risk factors associated with gallstones, like obesity, diabetes, alcohol consumption and fatty diet are the same involved in the pathogenesis of pancreatic cancer; for this reason some studies clear the role of biliary obstructive diseases (39).

Conclusions

Pancreatic cancer is one of the most oncological big killer; in few years it will become a non-marginal healthy problem, because of its increasing trend of incidence and poor prognosis after diagnosis. In several cases it is difficult to identify certain risk factors and the hereditary ones is clear just in small portion; the large majority of pancreatic cancer results from environmental factors: smoke, alcohol consumption, chronic pancreatitis, obesity and diabetes mellitus.
  36 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  The race from chronic pancreatitis to pancreatic cancer.

Authors:  Giulia Martina Cavestro; Giuseppe Comparato; Antonio Nouvenne; Mario Sianesi; Francesco Di Mario
Journal:  JOP       Date:  2003-09

Review 3.  Tobacco and the risk of pancreatic cancer: a review and meta-analysis.

Authors:  Simona Iodice; Sara Gandini; Patrick Maisonneuve; Albert B Lowenfels
Journal:  Langenbecks Arch Surg       Date:  2008-01-12       Impact factor: 3.445

4.  Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts.

Authors:  Tanja Stocks; Kilian Rapp; Tone Bjørge; Jonas Manjer; Hanno Ulmer; Randi Selmer; Annekatrin Lukanova; Dorthe Johansen; Hans Concin; Steinar Tretli; Göran Hallmans; Håkan Jonsson; Pär Stattin
Journal:  PLoS Med       Date:  2009-12-22       Impact factor: 11.069

5.  Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells.

Authors:  Jiayue Yang; Richard T Waldron; Hsin-Yuan Su; Aune Moro; Hui-Hua Chang; Guido Eibl; Kevin Ferreri; Fouad R Kandeel; Aurelia Lugea; Ling Li; Stephen J Pandol
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-08       Impact factor: 4.052

Review 6.  Increased Risk of Pancreatic Cancer Related to Gallstones and Cholecystectomy: A Systematic Review and Meta-Analysis.

Authors:  Yonggang Fan; Jie Hu; Bing Feng; Wei Wang; Guoliang Yao; Jingming Zhai; Xin Li
Journal:  Pancreas       Date:  2016-04       Impact factor: 3.327

7.  Risk of pancreatic cancer in families with Lynch syndrome.

Authors:  Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

Review 8.  Familial pancreatic cancer.

Authors:  Chanjuan Shi; Ralph H Hruban; Alison P Klein
Journal:  Arch Pathol Lab Med       Date:  2009-03       Impact factor: 5.534

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Gallstones, cholecystectomy, and the risk for developing pancreatic cancer.

Authors:  E S Schernhammer; D S Michaud; M F Leitzmann; E Giovannucci; G A Colditz; C S Fuchs
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

View more
  20 in total

Review 1.  Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon.

Authors:  Anna La Salvia; Irene Persano; Elena Parlagreco; Alessandro Audisio; Massimiliano Cani; Maria Pia Brizzi
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 2.  Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways.

Authors:  Carmen Bax; Beatrice Julia Lotesoriere; Selena Sironi; Laura Capelli
Journal:  Cancers (Basel)       Date:  2019-08-25       Impact factor: 6.639

3.  The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-10-21

4.  Increased Risk of Hospitalization for Pancreatic Cancer in the First 8 Years after a Gestational Diabetes Mellitus regardless of Subsequent Type 2 Diabetes: A Nationwide Population-Based Study.

Authors:  Julien Simon; Karine Goueslard; Patrick Arveux; Sonia Bechraoui-Quantin; Jean-Michel Petit; Catherine Quantin
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 5.  Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance.

Authors:  Bao Q Lam; Rashmi Srivastava; Jason Morvant; Sharmila Shankar; Rakesh K Srivastava
Journal:  Cells       Date:  2021-11-08       Impact factor: 6.600

Review 6.  Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy.

Authors:  Michail Galanopoulos; Aris Doukatas; Filippos Gkeros; Nikos Viazis; Christos Liatsos
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

7.  MicroRNA-4516 suppresses pancreatic cancer development via negatively regulating orthodenticle homeobox 1.

Authors:  Shuo Chen; Meng Xu; Jing Zhao; Jiaqi Shen; Junhui Li; Yang Liu; Gang Cao; Jiancang Ma; Weizhou He; Xi Chen; Tao Shan
Journal:  Int J Biol Sci       Date:  2020-05-18       Impact factor: 6.580

8.  The global burden of pancreatic cancer.

Authors:  Giuseppe Lippi; Camilla Mattiuzzi
Journal:  Arch Med Sci       Date:  2020-05-04       Impact factor: 3.318

Review 9.  Role of Nrf2 in Pancreatic Cancer.

Authors:  Marta Cykowiak; Violetta Krajka-Kuźniak
Journal:  Antioxidants (Basel)       Date:  2021-12-30

10.  Dynamic Doppler Ultrasound Assessment of Tissue Perfusion Is a Better Tool than a Single Vessel Doppler Examination in Differentiating Malignant and Inflammatory Pancreatic Lesions.

Authors:  Przemysław Dyrla; Arkadiusz Lubas; Jerzy Gil; Marek Saracyn; Maciej Gonciarz
Journal:  Diagnostics (Basel)       Date:  2021-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.